The TZDs are the agonist for PPAR-γ and promote insulin sensitization and improve dyslipidemia in patients with type 2 DM, although it is unknown how PPAR agonists-induced upregulation of UCPs contributes to their beneficial effects on CVD. The gene discussed is PPARG; the disease is metabolic syndrome.